153 related articles for article (PubMed ID: 38012520)
21. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Burkitt K; Ljungman M
Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
[TBL] [Abstract][Full Text] [Related]
22. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
23. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
24. Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles.
Dixit N; Vaibhav K; Pandey RS; Jain UK; Katare OP; Katyal A; Madan J
Biomed Pharmacother; 2015 Feb; 69():1-10. PubMed ID: 25661330
[TBL] [Abstract][Full Text] [Related]
25. Amplification of CyclinL1 in uterine cervical carcinoma has prognostic implications.
Mitra S; Mazumder Indra D; Basu PS; Mondal RK; Roy A; Roychoudhury S; Panda CK
Mol Carcinog; 2010 Nov; 49(11):935-43. PubMed ID: 20721974
[TBL] [Abstract][Full Text] [Related]
26. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
[TBL] [Abstract][Full Text] [Related]
27. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer.
Li J; Ping Z; Ning H
Int J Mol Sci; 2012 Nov; 13(12):16053-64. PubMed ID: 23443110
[TBL] [Abstract][Full Text] [Related]
28. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
Zhao M; Li X; Chen X
J Bioenerg Biomembr; 2021 Apr; 53(2):177-189. PubMed ID: 33538941
[TBL] [Abstract][Full Text] [Related]
29. SH3BP1-induced Rac-Wave2 pathway activation regulates cervical cancer cell migration, invasion, and chemoresistance to cisplatin.
Wang J; Feng Y; Chen X; Du Z; Jiang S; Ma S; Zou W
J Cell Biochem; 2018 Feb; 119(2):1733-1745. PubMed ID: 28786507
[TBL] [Abstract][Full Text] [Related]
30. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
[TBL] [Abstract][Full Text] [Related]
31. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.
Zhang J; Wang X; Lin CJ; Couch FJ; Fei P
Cancer Biol Ther; 2006 Dec; 5(12):1632-6. PubMed ID: 17106252
[TBL] [Abstract][Full Text] [Related]
33. Investigation of molecular mechanisms underlying JAK/STAT signaling pathway in HPV-induced cervical carcinogenesis using 'omics' approach.
Thakur K; Janjua D; Shishodia G; Chhokar A; Aggarwal N; Yadav J; Tripathi T; Chaudhary A; Senrung A; Bharti AC
Med Oncol; 2022 Oct; 39(12):255. PubMed ID: 36224441
[TBL] [Abstract][Full Text] [Related]
34. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
35. Deregulated TNF-Alpha Levels Along with HPV Genotype 16 Infection Are Associated with Pathogenesis of Cervical Neoplasia in Northeast Indian Patients.
Das CR; Tiwari D; Dongre A; Khan MA; Husain SA; Sarma A; Bose S; Bose PD
Viral Immunol; 2018 May; 31(4):282-291. PubMed ID: 29608425
[TBL] [Abstract][Full Text] [Related]
36. Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines.
Sood S; Srinivasan R
Mol Cell Biochem; 2015 Jun; 404(1-2):181-91. PubMed ID: 25772483
[TBL] [Abstract][Full Text] [Related]
37. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
38. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer.
Fang X; Zhong G; Wang Y; Lin Z; Lin R; Yao T
Cell Death Dis; 2020 Jul; 11(7):531. PubMed ID: 32661236
[TBL] [Abstract][Full Text] [Related]
39. hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin.
Nakamura M; Kyo S; Kanaya T; Yatabe N; Maida Y; Tanaka M; Ishida Y; Fujii C; Kondo T; Inoue M; Mukaida N
Cancer Gene Ther; 2004 Jan; 11(1):1-7. PubMed ID: 14681721
[TBL] [Abstract][Full Text] [Related]
40. Deregulation of H19 is associated with cervical carcinoma.
Roychowdhury A; Samadder S; Das P; Mazumder DI; Chatterjee A; Addya S; Mondal R; Roy A; Roychoudhury S; Panda CK
Genomics; 2020 Jan; 112(1):961-970. PubMed ID: 31229557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
